Talat Imran sold $11k of RANI
Chief Executive Officer at Rani Therapeutics Holdings, Inc.. 8,014 shares at an average of $1.41, traded Dec 27, 2024, filed Jul 21, 2026.
Score components
- +25RoleCEO
- 0Trade size$11k at market
- 0Share of holdings soldSold 1.6% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001869579-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 27, 2024 | SOpen-market sale Class A Common Stock | -8,014 | $1.41 | $11k | 486,737 | Jul 21, 2026 |
| Jun 27, 2025 | FTax withholding Class A Common Stock | -9,076 | $0.55 | $4,992 | 477,661 | Jul 21, 2026 |
| Sep 27, 2025 | FTax withholding Class A Common Stock | -9,077 | $0.48 | $4,357 | 468,584 | Jul 21, 2026 |
| Dec 27, 2025 | FTax withholding Class A Common Stock | -7,906 | $1.40 | $11k | 460,678 | Jul 21, 2026 |
| Mar 22, 2026 | FTax withholding Class A Common Stock | -8,916 | $1.13 | $10k | 451,762 | Jul 21, 2026 |
| Mar 27, 2026 | FTax withholding Class A Common Stock | -9,099 | $0.81 | $7,370 | 442,663 | Jul 21, 2026 |
| Jun 27, 2026 | FTax withholding Class A Common Stock | -7,927 | $0.74 | $5,866 | 434,736 | Jul 21, 2026 |
Related signals
Other insiders at Rani Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | Rani Therapeutics Holdings, Inc. | Mir A Imran director, owner | $25k 36,000 shares | +2% | |
| 49Moderate | Rani Therapeutics Holdings, Inc. | Talat Imran Chief Executive Officer | $25k 35,000 shares | +8% | |
| 15Weak | RANIsell Rani Therapeutics Holdings, Inc. | Alireza Javadi Chief Technical Officer | $301 386 shares | -4% | |
| 52Moderate | RANIbuy Rani Therapeutics Holdings, Inc. | Mir A Imran director, owner | $1.3M 2,083,334 shares | - | |
| 57Moderate | RANIsell Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership owner | $16M 5,923,000 shares | -71% | |
| 36Weak | Rani Therapeutics Holdings, Inc. | Kate McKinley Chief Business Officer | $30k 17,960 shares | - | |
| 33Weak | Rani Therapeutics Holdings, Inc. | Talat Imran Chief Executive Officer | $20k 10,296 shares | +2% | |
| 47Moderate | RANIsell Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership owner | $10M 3,829,360 shares | -32% | |
| 57Moderate | RANIsell Rani Therapeutics Holdings, Inc. | Cortes Isidoro Alfonso Quiroga owner | $11M 5,265,165 shares | -100% | |
| 75Notable | Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership owner | $11M 5,265,165 shares | +77% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.